KT501 not checked

Kali Therapeutics, Inc.

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 1 trial completes
Trials
1 active
1 in total
Targets
CD19 · BCMA · CD3
 

What this is

How it works
How it works isn't classified yet
How it’s given
“KT501 is a monoclonal antibody that depletes B cells including plasma cells by targeting CD19, BCMA and CD3.”In the company’s words, NCT07234773 on ClinicalTrials.gov
Tested for
Rheumatoid Arthritis (RA)
Main trialPhase 1
“This is a Phase 1, open-label, first-in-human study to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of KT501 administered subcutaneously to participants with Rheumatoid Arthritis (RA).”In the company’s words, NCT07234773 on ClinicalTrials.gov

Other drugs for Rheumatoid Arthritis (RA)

All 80 drugs for Rheumatoid Arthritis (RA)

Coming up1

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials1

TrialPhaseCompletesWhat it tests
Phase 1Recruiting Feb 2027 A First-in-human Study of KT501 Administered Subcutaneously to Patients With Rheumatoid Arthritis (RA).
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 20 Nov 2026 · EU trials register (CTIS) updated 20 Nov 2026 · openFDA updated 20 Nov 2026

Follow KT501

Following is part of Solo: you see every change to KT501 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in